RT Journal Article
SR Electronic
A1 Vinall, Maria
T1 Treatment with Alemtuzumab Leads to Durable Benefits in Patients with Multiple Sclerosis
JF MD Conference Express
YR 2014
FD SAGE Publications
VO 14
IS 6
SP 9
OP 9
DO 10.1177/155989771406004
UL http://mdc.sagepub.com/content/14/6/9.1.abstract
AB Treatment with alemtuzumab is associated with durable improvements in magnetic resonance imaging (MRI) disease activity in patients with active relapsing-remitting multiple sclerosis. This article presents the 3-year results from An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab (NCT00930553), an ongoing extension study of the Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis (CARE-MS) series of studies.